Bigelow Investment Advisors LLC Sells 600 Shares of Pfizer Inc. (NYSE:PFE)

Bigelow Investment Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,777 shares of the biopharmaceutical company’s stock after selling 600 shares during the period. Bigelow Investment Advisors LLC’s holdings in Pfizer were worth $861,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of PFE. Gilbert & Cook Inc. grew its holdings in shares of Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares during the last quarter. Gryphon Financial Partners LLC increased its holdings in shares of Pfizer by 43.7% during the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 8,194 shares in the last quarter. Fiera Capital Corp bought a new position in shares of Pfizer in the 4th quarter valued at $718,000. First Heartland Consultants Inc. grew its position in Pfizer by 43.3% during the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 3,933 shares during the last quarter. Finally, Private Wealth Management Group LLC bought a new position in Pfizer in the 4th quarter valued at approximately $98,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $29.27 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a 50-day moving average of $29.21 and a 200-day moving average of $28.11. Pfizer Inc. has a one year low of $25.20 and a one year high of $34.42. The company has a market cap of $165.86 billion, a P/E ratio of -487.75, a P/E/G ratio of 1.04 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the prior year, the company posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.74%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PFE. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, September 9th. Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group lifted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.